Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma ...Middle East

Data showed an excellent safety profile with no adverse events among the five subjects treated. Company continues to explore doses in the ongoing Phase II dose escalation study GAITHERSBURG, Md and SUZHOU, China, Aug. 29, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or...

Read More Details
Finally We wish PressBee provided you with enough information of ( Sirnaomics Achieves 100% Complete Response in Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma )

Also on site :

• World Leaders Cautiously Welcome Israel-Iran Cease-Fire
• '80s 'Adventures in Babysitting' Movie Siblings Reunite and Fans Can't Get Enough
• Iran’s Capital Tehran Endures Intense Attacks Before Cease-Fire With Israel